Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Effects of SGLT2 Inhibitors on Lipid Metabolism
Zsolt Szekeres, Kálmán Tóth, Eszter Szabados
Metabolites (2021) Vol. 11, Iss. 2, pp. 87-87
Open Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Neuroprotective Effect of SGLT2 Inhibitors
Agnieszka Pawlos, Marlena Broncel, Ewelina Woźniak, et al.
Molecules (2021) Vol. 26, Iss. 23, pp. 7213-7213
Open Access | Times Cited: 167
Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3587-3587
Open Access | Times Cited: 146
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 145
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis
Celestino Sardu, Maria Consiglia Trotta, Ferdinando Carlo Sasso, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Anna Martin, Sonja Lang, Tobias Goeser, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 7, pp. 533-546
Open Access | Times Cited: 48
Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system
Xin Chen, Denis Delić, Yaochen Cao, et al.
AJP Cell Physiology (2023) Vol. 324, Iss. 4, pp. C951-C962
Open Access | Times Cited: 31
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Jiang Li, Yuefeng Yu, Ying Sun, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102181-102181
Open Access | Times Cited: 25
SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study
Yanchen Lv, Xin Cheng, Qiang Dong
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients
Pojsakorn Danpanichkul, Worapaka Manosroi, Tharadon Nilsirisuk, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 9
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6218-6218
Open Access | Times Cited: 8
Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
Habib Yaribeygi, Mina Maleki, Željko Reiner, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6544-6544
Open Access | Times Cited: 28
Programmed cell death and lipid metabolism of macrophages in NAFLD
Zhun Xiao, Minghao Liu, Fangming Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Atrial Cardiomyopathy in Valvular Heart Disease: From Molecular Biology to Clinical Perspectives
Andrea Molnár, Attila Sánta, Dorottya Pásztor, et al.
Cells (2023) Vol. 12, Iss. 13, pp. 1796-1796
Open Access | Times Cited: 16
Emerging therapies for MASLD and their impact on plasma lipids
Madison Nguyen, Amon Asgharpour, Dave L. Dixon, et al.
American Journal of Preventive Cardiology (2024) Vol. 17, pp. 100638-100638
Open Access | Times Cited: 7
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Mariam M. Ali, Sanober Parveen, Vanessa Williams, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100341-100341
Open Access | Times Cited: 7
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 7
Reno-protective Effects of Empagliflozin in High Fat Diet Induced Obesity-Related Glomerulopathy by Regulation of Gut-Kidney Axis
Lei Lei, Ting Zhu, Tian-Jiao Cui, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 4, pp. C994-C1011
Open Access | Times Cited: 6
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial
Kayo Horibe, Katsutaro Morino, Itsuko Miyazawa, et al.
Diabetes Research and Clinical Practice (2022) Vol. 186, pp. 109781-109781
Closed Access | Times Cited: 23
Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
Siarhei A. Dabravolski, Alexander D. Zhuravlev, Andrey G. Kartuesov, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5371-5371
Open Access | Times Cited: 23
Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
Zofia Wicik, A Nowak, Joanna Jarosz-Popek, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 23
SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Naser Safaie, Shahab Masoumi, Shaban Alizadeh, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 5
Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice
Qiong Yang, Ling Deng, Changmei Feng, et al.
PeerJ (2024) Vol. 12, pp. e17055-e17055
Open Access | Times Cited: 5
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
Sunetra Mondal, Subhodip Pramanik, Vibhu Ranjan Khare, et al.
World Journal of Cardiology (2024) Vol. 16, Iss. 5, pp. 240-259
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top